Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer.

Clemons M, Stober C, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Vandermeer L, Mazzarello S, Awan A, Basulaiman B, Robinson A, Mallick R, Hutton B, Fergusson D.

Support Care Cancer. 2020 Jan 30. doi: 10.1007/s00520-020-05326-y. [Epub ahead of print]

PMID:
32002617
2.

Benefits and harms of medical cannabis: a scoping review of systematic reviews.

Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, Clemons M, Kanji S, Hutton B.

Syst Rev. 2019 Dec 10;8(1):320. doi: 10.1186/s13643-019-1243-x.

3.

Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Buus R, Quang LH, Thi Han P, Khoa PH, Dinh NV, To TV, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Smith IE, Dowsett M.

NPJ Breast Cancer. 2019 Nov 15;5:42. doi: 10.1038/s41523-019-0138-2. eCollection 2019.

4.

Increased density and age-related sharing of synapses at the cone to OFF bipolar cell synapse in the mouse retina.

Simmons AB, Camerino MJ, Clemons MR, Sukeena JM, Bloomsburg S, Borghuis BG, Fuerst PG.

J Comp Neurol. 2019 Nov 13. doi: 10.1002/cne.24810. [Epub ahead of print]

PMID:
31721194
5.

Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.

Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN.

J Natl Cancer Inst. 2019 Oct 31. pii: djz215. doi: 10.1093/jnci/djz215. [Epub ahead of print]

PMID:
31693129
6.

A Critically Appraised Topic on the Tuck Jump Assessment: Does the Tuck Jump Assessment Demonstrate Interrater and Intrarater Reliability in Healthy Individuals?

Mason ML, Clemons MN, LaBarre KB, Szymczak NR, Chimera NJ.

J Sport Rehabil. 2019 Oct 16:1-6. doi: 10.1123/jsr.2019-0099. [Epub ahead of print]

PMID:
31624223
7.

Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.

Robertson SJ, Pond GR, Hilton J, Petkiewicz SL, Ayroud Y, Kos Z, Gravel DH, Stober C, Vandermeer L, Arnaout A, Clemons M.

Clin Breast Cancer. 2020 Feb;20(1):61-67. doi: 10.1016/j.clbc.2019.07.006. Epub 2019 Aug 22.

PMID:
31551182
8.

Exploring reasons for overuse of contralateral prophylactic mastectomy in Canada.

Squires JE, Simard SN, Asad S, Stacey D, Graham ID, Coughlin M, Clemons M, Grimshaw JM, Zhang J, Caudrelier JM, Arnaout A.

Curr Oncol. 2019 Aug;26(4):e439-e457. doi: 10.3747/co.26.4951. Epub 2019 Aug 1.

9.

Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.

Arnaout A, Robertson S, Pond GR, Vieth R, Jeong A, Hilton J, Ramsey T, Clemons M.

Breast Cancer Res Treat. 2019 Nov;178(2):347-356. doi: 10.1007/s10549-019-05392-9. Epub 2019 Aug 9.

PMID:
31399931
10.

A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy.

Robinson A, Stober C, Fergusson D, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Mazzarello S, Vandermeer L, Joy AA, Awan A, Basulaiman B, Mallick R, Hutton B, Clemons M; REaCT investigators.

Breast Cancer Res Treat. 2019 Nov;178(2):337-345. doi: 10.1007/s10549-019-05388-5. Epub 2019 Aug 7.

PMID:
31392518
11.

A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.

Arnaout A, Robertson SJ, Pond GR, Lee H, Jeong A, Ianni L, Kroeger L, Hilton J, Coupland S, Gottlieb C, Hurley B, McCarthy A, Clemons M.

Breast Cancer Res Treat. 2019 Nov;178(2):327-335. doi: 10.1007/s10549-019-05381-y. Epub 2019 Aug 7.

PMID:
31392517
12.

Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer.

de Lima MAG, Clemons M, Van Katwyk S, Stober C, Robertson SJ, Vandermeer L, Fergusson D, Thavorn K.

J Eval Clin Pract. 2019 Jul 9. doi: 10.1111/jep.13223. [Epub ahead of print]

PMID:
31287198
13.

Why "Reply All" Can Push All the Wrong Buttons.

McGee S, Clemons M, Joy AA, Hilton J, Jeong A, Robinson A.

Oncologist. 2019 Aug;24(8):e643-e645. doi: 10.1634/theoncologist.2019-0304. Epub 2019 Jun 4.

14.

Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).

Basulaiman B, Awan AA, Fergusson D, Vandermeer L, Arnaout A, Hilton J, Hutton B, Joy AA, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, Clemons M.

Breast Cancer Res Treat. 2019 Aug;177(1):93-101. doi: 10.1007/s10549-019-05274-0. Epub 2019 May 24. Review.

PMID:
31127468
15.

Health care insecurity in the underserved: Effect of a charitable pharmacy model.

Clemons MD, Casper KA, Seifert JL, Fahey HP, Li J.

J Am Pharm Assoc (2003). 2019 Jul - Aug;59(4S):S19-S24. doi: 10.1016/j.japh.2019.03.011. Epub 2019 May 9.

PMID:
31080150
16.

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.

Awan AA, Hutton B, Hilton J, Mazzarello S, Van Poznak C, Vandermeer L, Bota B, Stober C, Sienkiewicz M, Fergusson D, Shorr R, Clemons M.

Breast Cancer Res Treat. 2019 Aug;176(3):507-517. doi: 10.1007/s10549-019-05265-1. Epub 2019 May 11.

PMID:
31079283
17.

Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists.

Thangarasa T, Gotfrit J, Goodwin RA, Tang PA, Clemons M, Imbulgoda A, Vickers MM.

Curr Oncol. 2019 Apr;26(2):e162-e166. doi: 10.3747/co.26.4591. Epub 2019 Apr 1.

18.

Patient decision aid for contralateral prophylactic mastectomy for use in the consultation: a feasibility study.

Squires JE, Stacey D, Coughlin M, Greenough M, Roberts A, Dorrance K, Clemons M, Caudrelier JM, Graham ID, Zhang J, Varin MD, Arnaout A.

Curr Oncol. 2019 Apr;26(2):137-148. doi: 10.3747/co.26.4689. Epub 2019 Apr 1.

19.

Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.

Robertson SJ, Ibrahim MFK, Stober C, Hilton J, Kos Z, Mazzarello S, Ramsay T, Fergusson D, Vandermeer L, Mallick R, Arnaout A, Dent SF, Segal R, Sehdev S, Gertler S, Hutton B, Clemons M.

J Eval Clin Pract. 2019 Apr;25(2):196-204. doi: 10.1111/jep.13094. Epub 2019 Jan 23.

PMID:
30672056
20.

Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others".

Basulaiman B, Awan A, Hilton JF, Clemons M.

Curr Oncol. 2018 Dec;25(6):355-357. doi: 10.3747/co.25.4587. Epub 2018 Dec 1. No abstract available.

21.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2019 Apr;27(4):1563-1572. doi: 10.1007/s00520-018-4567-5. Epub 2018 Nov 30.

PMID:
30506102
22.

A group I metabotropic glutamate receptor controls synaptic gain between rods and rod bipolar cells in the mouse retina.

Hellmer CB, Clemons MR, Nawy S, Ichinose T.

Physiol Rep. 2018 Oct;6(20):e13885. doi: 10.14814/phy2.13885.

23.

Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients.

McGee SF, Vandermeer L, Mazzarello S, Sienkiewicz M, Stober C, Hutton B, Fergusson D, Hilton J, Caudrelier JM, Blanchette P, Clemons M.

Clin Breast Cancer. 2019 Feb;19(1):e40-e47. doi: 10.1016/j.clbc.2018.08.012. Epub 2018 Sep 4.

PMID:
30318304
24.

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.

Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, Clemons M.

J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.

25.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
26.

Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer-a patient survey.

LeVasseur N, Stober C, Ibrahim M, Gertler S, Hilton J, Robinson A, McDiarmid S, Fergusson D, Mazzarello S, Hutton B, Joy AA, McInnes M, Clemons M.

Curr Oncol. 2018 Aug;25(4):e305-e310. doi: 10.3747/co.25.3911. Epub 2018 Aug 14.

27.

Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians.

LeVasseur N, Stober C, Daigle K, Robinson A, McDiarmid S, Mazzarello S, Hutton B, Joy A, Fergusson D, Hilton J, McInnes M, Clemons M.

Curr Oncol. 2018 Aug;25(4):e298-e304. doi: 10.3747/co.25.3903. Epub 2018 Aug 14.

28.

Unnecessary variation in practice: how to improve cancer care through pragmatic trials.

LeVasseur N, Fergusson D, Clemons M.

Curr Oncol. 2018 Aug;25(4):e263-e264. doi: 10.3747/co.25.3922. Epub 2018 Aug 14. No abstract available.

29.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D.

Support Care Cancer. 2019 Apr;27(4):1345-1354. doi: 10.1007/s00520-018-4408-6. Epub 2018 Aug 11.

PMID:
30099602
30.

De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?

Awan AA, Paterson A, Clemons M.

J Oncol Pract. 2018 Aug;14(8):465-467. doi: 10.1200/JOP.18.00393. No abstract available.

PMID:
30096270
31.

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

Hilton J, Stober C, Mazzarello S, Vandermeer L, Fergusson D, Hutton B, Clemons M.

PLoS One. 2018 Jul 24;13(7):e0199297. doi: 10.1371/journal.pone.0199297. eCollection 2018.

32.

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review.

McGee SF, Mazzarello S, Caudrelier JM, Lima MAG, Hutton B, Sienkiewicz M, Stober C, Fernandes R, Ibrahim MFK, Vandermeer L, Hilton J, Shorr R, Fergusson D, Clemons M.

Cancer Treat Rev. 2018 Sep;69:132-142. doi: 10.1016/j.ctrv.2018.06.015. Epub 2018 Jun 28. Review.

PMID:
30014951
33.

Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.

Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, Joy AA, Fergusson D, McDiarmid S, McInnes M, Shorr R, Clemons M.

Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4. Review.

PMID:
29974358
34.

Poor outcomes after venous thromboembolism in cancer patients: It's time to change practice.

Delluc A, Clemons M.

Thromb Res. 2018 Nov;171:177-178. doi: 10.1016/j.thromres.2018.06.003. Epub 2018 Jun 2. No abstract available.

PMID:
29880445
35.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.

36.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.

Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M.

Support Care Cancer. 2018 Sep;26(9):3073-3081. doi: 10.1007/s00520-018-4161-x. Epub 2018 Mar 21.

PMID:
29564623
37.

Guidelines versus individualized care for the management of CINV.

Clemons M.

Support Care Cancer. 2018 Mar;26(Suppl 1):11-17. doi: 10.1007/s00520-018-4115-3. Epub 2018 Mar 19.

38.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-CME information.

Aapro M, Clemons M, Schwartzberg L, Warr D.

Support Care Cancer. 2018 Mar;26(Suppl 1):1-2. doi: 10.1007/s00520-018-4122-4. Epub 2018 Mar 19. No abstract available.

PMID:
29556807
39.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

40.

Should de-escalation of bone-targeting agents be standard of care?

Awan A, Hutton B, Clemons M.

Ann Oncol. 2018 May 1;29(5):1333-1334. doi: 10.1093/annonc/mdy068. No abstract available.

41.

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.

Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M.

Support Care Cancer. 2018 Jul;26(7):2323-2331. doi: 10.1007/s00520-018-4074-8. Epub 2018 Feb 6.

PMID:
29411131
42.

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.

Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M.

Breast Cancer Res Treat. 2018 Apr;168(2):371-379. doi: 10.1007/s10549-017-4604-y. Epub 2017 Dec 6.

PMID:
29214415
43.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

44.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.

45.

What we learned in kindergarten: five tips for collaboration in oncology.

Arnaout A, Joy AA, Juliao M, Clemons M.

Curr Oncol. 2017 Oct;24(5):e437-e440. doi: 10.3747/co.24.3675. Epub 2017 Oct 25. No abstract available.

46.

Generating Medical Student Interest in the Field of Radiology.

Taylor CS, Weatherly B, Farley EP, Clemons MP, Watts J, Vijayakumar V.

J Am Coll Radiol. 2018 Feb;15(2):340-342. doi: 10.1016/j.jacr.2017.08.018. Epub 2017 Oct 24. No abstract available.

PMID:
29079247
47.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.

PMID:
29035643
48.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
49.

Physician "out of office" alert: does it work?

Clemons M, Joy AA, Hilton J, Arnaout A, Brackstone M, Wheatley-Price P, Stober C, Dinniwell R, Mazzarello S, da Costa M, Hutton B.

Curr Oncol. 2017 Jun;24(3):e176-e179. doi: 10.3747/co.24.3548. Epub 2017 Jun 27. No abstract available.

50.

Reply to T.J. Powles et al.

Dhesy-Thind S, Fletcher GG, Clemons M, Van Poznak C; Cancer Care Ontario–American Society of Clinical Oncology Adjuvant Bone-Modifying Agents Panel.

J Clin Oncol. 2017 Aug 10;35(23):2720-2721. doi: 10.1200/JCO.2017.73.8567. Epub 2017 Jun 27. No abstract available.

PMID:
28654367

Supplemental Content

Loading ...
Support Center